Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections in the lung, urinary tract or wounds; LSALT, a potential treatment for inflammation, sepsis and cancer metastasis; and, 'Borg' peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics. For more information on Arch Biopartners, its technologies and other public documents Arch has filed at www.SEDAR.com , please visit www.archbiopartners.com .